BRILINTA PEGASUS STUDY MEETS PRIMARY ENDPOINT

PEGASUS-TIMI 54 STUDY OF BRILINTA® MEETS

PRIMARY ENDPOINT IN BOTH 60MG AND 90MG DOSES



Both BRILINTA 60mg and 90mg demonstrate statistically significant reduction in
major cardiovascular thrombotic events in patients with a history of heart
attack

AstraZeneca today announced that the PEGASUS-TIMI 54 study, a large scale
outcomes trial involving over 21,000 patients, successfully met its primary
efficacy endpoint. The study assessed BRILINTA® (ticagrelor) tablets at either
60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary
prevention of atherothrombotic events in patients who had experienced a heart
attack one to three years prior to study start. The primary efficacy endpoint
was a composite of cardiovascular (CV) death, myocardial infarction (MI) or
stroke.

Preliminary analysis did not reveal any unexpected safety issues. Full
evaluation of the data is ongoing.

Elisabeth Björk, Vice President, Head of Cardiovascular and Metabolic Diseases,
Global Medicines Development, AstraZeneca, said: "We are very pleased with the
top line results of the PEGASUS-TIMI 54 study, the second positive major
outcomes study in the PARTHENON programme. The results build on existing
understanding of the benefits of BRILINTA for patients with acute coronary
syndrome and offer important clinical insights into its potential role for the
longer term prevention of cardiovascular events. We look forward to presenting
the data later this year."

The PEGASUS-TIMI 54 study investigated two different doses of ticagrelor on a
background of low dose aspirin versus placebo plus low dose aspirin, in patients
aged 50 and older with a history of heart attack and one additional CV risk
factor1. The study was designed to better understand the management of patients
more than 12 months after their heart attack, who remain at high risk for major
thrombotic events.

Complete results from the PEGASUS-TIMI 54 study will be submitted to a
scientific meeting in 2015 and pending further analysis, AstraZeneca plans to
file this data with regulatory health authorities. Ticagrelor is not approved
for secondary prevention of atherothrombotic events in patients with a history
of heart attack beyond one year.

The PEGASUS-TIMI 54 study is part of AstraZeneca's PARTHENON programme. The
PLATO study, involving over 18,000 patients, was the first study in the
programme and is the basis on which ticagrelor has been approved in over 100
countries and included in 12 major ACS treatment guidelines globally. Further
ongoing PARTHENON studies are assessing ticagrelor for the prevention of
cardiovascular events in patients with peripheral arterial disease, ischaemic
stroke or transient ischaemic attack, and in patients with diabetes and coronary
atherosclerosis.

1 Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the
Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using
Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in
Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014;167:437-44.

About PEGASUS-TIMI 54

PEGASUS-TIMI 54 (PrEvention with TicaGrelor of SecondAry Thrombotic Events in
High-RiSk Patients with Prior AcUte Coronary Syndrome - Thrombolysis In
Myocardial Infarction Study Group) is one of AstraZeneca's largest ever outcomes
trials with more than 21,000 patients from over 1,100 sites in 31 countries in
Europe, the Americas, Africa and  Australia/Asia. It was conducted in
collaboration with the Thrombolysis in Myocardial Infarction (TIMI) Study Group
from Brigham and Women's Hospital (Boston, MA, USA).

About the PARTHENON programme

The PEGASUS study is part of PARTHENON, the largest ever AstraZeneca
cardiovascular outcomes programme, involving nearly 80,000 patients at high risk
of cardiovascular events (MI, stroke and/or cardiovascular death) due to their
underlying disease. PARTHENON

aims to enhance scientific understanding of the role of ticagrelor in the
treatment of atherothrombotic conditions. It includes five key studies covering
broad patient populations across varying timescales. The studies encompass a
wide range of cardiovascular disorders, including stroke/transient ischaemic
attack (SOCRATES), peripheral arterial disease (EUCLID) and patients with type 2
diabetes at high risk of cardiovascular events (THEMIS).

The PARTHENON programme aims to support four new indications for ticagrelor over
the next 4 years.

About BRILINTA®

BRILINTA is a direct-acting P2Y12 receptor antagonist in a chemical class called
cyclo-pentyl-triazolo-pyrimidines (CPTPs). BRILINTA works by inhibiting platelet
activation and has been shown to reduce the rate of thrombotic CV events, such
as a heart attack or CV death, in patients with acute coronary syndrome (ACS).

BRILINTA (90mg) is indicated to reduce the rate of thrombotic CV events in
patients with ACS (unstable angina [UA], non-ST-elevation myocardial infarction
[NSTEMI], or ST-elevation myocardial infarction [STEMI]). BRILINTA has been
shown to reduce the rate of a combined end point of CV death, MI, or stroke
compared to clopidogrel. The difference between treatments was driven by CV
death and MI with no difference in stroke. In patients treated with percutaneous
coronary intervention, it also reduces the rate of stent thrombosis.

BRILINTA is a registered trademark of the AstraZeneca group.

About the Thrombolysis in Myocardial Infarction (TIMI) Study Group

The TIMI Study Group is affiliated with Brigham and Women's Hospital and Harvard
Medical School and is located in Boston, Massachusetts. It is one of the oldest
cardiovascular academic research organisation in the United States and has
conducted numerous practice-changing clinical trials in patients with CV disease
or risk factors for CV disease.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com



CONTACTS

Media Enquiries

Esra Erkal-Paler                         +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                        +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                         +44 20 7604 8034 (UK/Global)

Jacob Lund                                 +46 8 553 260 20 (Sweden)

Michele Meixell                            + 1 302 885 6351 (US)

Investor Enquiries

Thomas Kudsk Larsen               +44 20 7604 8199    mob: +44 7818 524185


Karl Hård                                     +44 20 7604 8123 mob: +44 7789
654364

Eugenia Litz                                +44 20 7604 8233    mob: +44 7884
735627

Craig Marks                                +44 20 7 604 8591   mob: +44 7881
615764

Christer Gruvris                         +44 20 7604 8126    mob: +44 7827
836825

14 January 2015

- ENDS -